KLOW Blend (GHK-Cu + BPC-157 + TB-500 + KPV)

Overview

Pre-mixed four-compound blend adding KPV (the C-terminal tripeptide of α-MSH) to the GLOW stack (GHK-Cu + BPC-157 + TB-500). This blend is not clinically validated; the evidence base is inferred from individual component peptides. No controlled human trial has tested this combination.

Mechanism of Action

Extrapolated from component-level preclinical data: KPV has been reported in animal colitis models to suppress NF-κB and proinflammatory cytokines, on top of the GLOW-stack component mechanisms. Additive or synergistic effects in humans have not been demonstrated.

Research Summary

Vendor-created formulation building on the GLOW blend with the addition of KPV. No published human research on this four-compound combination. Component evidence is predominantly preclinical.

Dosing Information

Reported Side Effects

• See individual compound profiles for GHK-Cu, BPC-157, TB-500, and KPV